Page 20 - Aet News Today

Instacart and DispatchHealth recently launched a partnership that allows DispatchHealth to provide food interventions to patients in need of nutrition support.

Sanofi and Synthekine will work together to develop cytokine therapies for inflammatory diseases. This new alliance comes as Sanofi is salvaging a different cytokine therapy that showed disappointing efficacy in Phase 2 after the pharma giant acquired it in a $2.5 billion deal.

This month, the World Health Organization released new guidelines on the ethics and governance of LLMs in healthcare. Reactions from the leaders of healthcare AI companies have been mainly positive. However, one leader pointed out that fear or the risks associated with LLMs shouldn't hinder innovation, and another noted that the guidance may have failed to mention a major topic.

Shore Capital reaffirmed their not rated rating on shares of Afentra (LON:AET – Free Report) in a research note published on Wednesday morning, Marketbeat.com reports. Afentra Price Performance AET stock opened at GBX 37 ($0.47) on Wednesday. The stock’s fifty day simple moving average is GBX 34.11 and its two-hundred day simple moving average is […]

Health system VC arms appear to have a lot more to offer to startups than traditional VC funds. Startup founders say that the tech pilots they launch with their health system partners end up being more effective because they are more incentive-aligned. For health systems, investing in a startup allows them to have a hand in shaping the tools they will eventually deploy across their enterprises to solve issues like burnout, payment delays and excessive hospital readmissions.

Insulin prices have long been a pain point for diabetics. The big three insulin manufacturers have cut prices across their product lineups, but potential competition from other biosimilar insulins is still in earlier stages of development.

As the food as medicine movement grows, some payers and healthcare organizations are carving out specific roles and teams dedicated to food and nutrition. Doing so can be beneficial considering the significant impact diet can have on health outcomes.

Shore Capital reiterated their not rated rating on shares of Afentra (LON:AET – Free Report) in a report issued on Wednesday, MarketBeat Ratings reports. Afentra Price Performance AET opened at GBX 37 ($0.47) on Wednesday. The company has a debt-to-equity ratio of 48.33, a current ratio of 1.46 and a quick ratio of 28.92. The […]

The shift towards digital pathology has marked a significant advancement in breast cancer diagnosis. High-resolution digital imaging of slides provides pathologists with an unprecedentedly clear and expansive view of tissue samples for their analysis.

ArriVent BioPharma will apply the IPO cash toward furmonertinib, which the biotech says could offer advantages over Takeda Pharmaceutical and Johnson & Johnson drugs that address the same lung cancer target. It’s the second biotech IPO of this week, following CG Oncology.